Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Krka Spells Out Chinese Potential With Plans To Double Portfolio In 2022
Slovenian Firm Also Plans To Regroup In West Europe After 11% Sales Tumble
Jan 28 2022
•
By
Dean Rudge
Krka launched pregabalin in China in 2021 • Source: Shutterstock
More from Earnings
More from Business